SeaStar Medical to Hold Business Update Conference Call Today at 4:00 p.m. Eastern Time
August 22 2023 - 8:00AM
SeaStar
Medical Holding Corporation (Nasdaq: ICU)
(“SeaStar Medical” or the “Company”), a medical device company
developing proprietary solutions to reduce the consequences of
hyperinflammation on vital organs, announces that management will
hold a business update conference call today at 4:00 p.m. Eastern
time (1:00 p.m. Pacific time). During the call, management will
provide a clinical and regulatory update and review the Company’s
value proposition, including the commercial opportunity.
A slide presentation to accompany management’s
prepared remarks will be available on the webcast and on the Events
and Presentations page of the Investors section of the SeaStar
Medical website at seastarmedical.com.
Date: Today, Tuesday, August 22, 2023 Time: 4:00
p.m. Eastern time (1:00 p.m. Pacific time)
Participants can pre-register for the conference
call here. Callers who pre-register will be given a conference
passcode and unique PIN to gain immediate access to the call and
bypass the live operator. Participants may pre-register at any
time, including up to and after the call start time.
Stockholders and other interested parties may
also participate in the conference call by dialing 866-777-2509
from within the U.S. or 412-317-5413 from outside the U.S., and
requesting the SeaStar Medical call.
A live webcast of the call will be available
here and will be archived for 90 days. A replay of the call will be
available beginning two hours after the call ends through August
24, 2023 by dialing 877-344-7529 from within the U.S., 855-669-9658
from Canada or 412-317-0088 from outside the U.S. and Canada, and
entering the conference identification number 8122409.
About SeaStar
Medical
SeaStar Medical is a medical technology company
that is redefining how extracorporeal therapies may reduce the
consequences of excessive inflammation on vital organs. SeaStar
Medical’s novel technologies rely on science and innovation to
provide life-saving solutions to critically ill patients. The
Company is developing and commercializing cell-directed
extracorporeal therapies that target the effector cells that drive
systemic inflammation, causing direct tissue damage and secreting a
range of pro-inflammatory cytokines that initiate and propagate
imbalanced immune responses. For more information visit
www.seastarmedical.com or visit us on LinkedIn or Twitter.
Contact:LHA Investor
RelationsJody Cain(310) 691-7100Jcain@lhai.com
# # #
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From Apr 2024 to May 2024
SeaStar Medical (NASDAQ:ICU)
Historical Stock Chart
From May 2023 to May 2024